Literature DB >> 8759674

Vanishing bile duct syndrome temporally associated with ibuprofen use.

I Alam1, L D Ferrell, N M Bass.   

Abstract

Nonsteroidal anti-inflammatory drugs are widely used, but the potential hepatotoxic side effects are not always appreciated. Herein, we report the first case, to our knowledge, of an atopic patient in whom severe cholestatic jaundice from bile ductopenia developed 3 wk after initiation of ibuprofen therapy. This drug-induced vanishing bile duct syndrome is probably an immunological (hypersensitivity) reaction. Vanishing bile duct syndrome as a consequence of ibuprofen use should be considered as a potential cause of chronic cholestasis when other more common etiologies have been excluded.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759674

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid.

Authors:  J P Richardet; A Mallat; E S Zafrani; M Blazquez; J C Bognel; B Campillo
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

2.  Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.

Authors:  Matthew Mason; Oyedele Adeyi; Scott Fung; Barbara-Ann Millar
Journal:  BMJ Case Rep       Date:  2014-11-28

Review 3.  Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

Authors:  Fernando Bessone
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

4.  Ibuprofen associated acute vanishing bile duct syndrome and toxic epidermal necrolysis in an infant.

Authors:  Hye-young Kim; Hea Kyoung Yang; Seong Heon Kim; Jae Hong Park
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

5.  Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report.

Authors:  Wen Xie; Qi Wang; Yuanjiao Gao; Calvin Q Pan
Journal:  BMC Gastroenterol       Date:  2018-09-29       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.